Trial Profile
A Phase 1 Study to Evaluate the Dose, Safety and Tolerability of an Intraperitoneal α-emitting Radionuclide Therapy (Radspherin) in Subjects With Peritoneal Carcinomatosis From Colorectal Carcinoma Following Hyperthermic Intraperitoneal Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Radspherin (Primary)
- Indications Carcinoma; Colorectal cancer; Peritoneal cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Oncoinvent
- 27 Oct 2023 According to an Oncoinvent media release, company announced the IND clearance for Radspherin for colorectal cancer patients following the promising indications of safety and efficacy from the RAD-18-002 Phase 1/2a clinical trial.
- 04 Oct 2023 According to Oncoinvent media release, At 18 months, none of the patients administered Radspherin at the recommended dose experienced peritoneal recurrences.
- 04 Oct 2023 Results presented in an Oncoinvent media release.